Oncotelic Therapeutics (OTCQB: OTLC) is positioned at the heart of the evolving landscape of pharmaceutical innovation, applying ultra-small carrier technologies to elevate existing cancer therapies. “The company is pioneering how nanotechnology can enhance bioavailability, precision targeting and therapeutic performance of anticancer compounds,” reads a recent article. “The advantages of nanoparticle delivery in pharma are significant… The contemporary view holds that nanocarrier-enabled formulations may be as transformative for drug delivery as the advent of monoclonal antibodies was for biologics… Into this context, Oncotelic Therapeutics, which in its most recent news has advanced nanoparticle-based delivery strategies through its joint venture entity, involving its Deciparticle(TM) platform. The company is now preparing its first-in-human study of an intravenous Everolimus (Afinitor(R)) nanoformulation (Sapu-003) that it codevelops via its subsidiary/partner Sapu Nano. According to the company, Sapu003 is designed to overcome the absorption and tumor-penetration limits of conventional oral Everolimus (Afinitor(R)) by delivering full bioavailability via intravenous nanoparticle delivery.”
NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at https://nnw.fm/OTLC
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer